Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548290 | 0.90 | KMT2A (0.71) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL11479783 | 0.87 | KMT2A (0.67) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5656878 | 0.85 | RAB9A (0.61) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL16254590 | 0.85 | KMT2A (0.65) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6359808 | 0.84 | RAB9A (0.60) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL17057207 | 0.84 | KMT2A (0.83) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL425351 | 0.84 | SMN1; SMN2 (0.57) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL22838012 | 0.84 | KMT2A (0.63) | RAB9ANPC1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL9911470 | 0.83 | RAB9A (0.56) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13612784 | 0.83 | RAB9A (0.56) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578322-B2 | Methods and consumer products for detecting a metabolite | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4237090-B1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | UNIV TEXAS (US) | 2026-02-18 | — | — | EP | claimed |
| CN-119968213-A | Methods for detecting and treating ovarian cancer | 德州大学系统董事会 | 2025-05-09 | — | — | CN | claimed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-20240044902-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | claimed |
| US-20230417734-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4237090-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | Board of Regents, The University of Texas System (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-116490776-A | Methods for detecting and treating ovarian cancer | 德州大学系统董事会 | 2023-07-25 | — | — | CN | claimed |
| WO-2022125057-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022093960-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | WO | claimed |
| EP-3967217-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| CN-113156096-A | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-07-23 | — | — | CN | claimed |
| CN-107427221-B | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-03-09 | — | — | CN | claimed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| EP-3990899-B1 | QUANTITATIVE RAMAN SPECTROSCOPY | AALTO UNIV FOUNDATION SR (FI) | 2026-05-20 | — | — | EP | disclosed |
| US-12578322-B2 | Methods and consumer products for detecting a metabolite | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12578322-B2 | Methods and consumer products for detecting a metabolite | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12571737-B2 | Quantitative Raman spectroscopy | AALTO UNIVERSITY FOUNDATION SR (FI) | 2026-03-10 | — | — | US | disclosed |
| US-12566161-B2 | Methods and consumer products for detecting a metabolite | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4237090-B1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | UNIV TEXAS (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4604968-A1 | ENHANCED NAD+ COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Bionadrx Holdings, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-119968213-A | Methods for detecting and treating ovarian cancer | 德州大学系统董事会 | 2025-05-09 | — | — | CN | disclosed |
| CN-119968213-A | Methods for detecting and treating ovarian cancer | 德州大学系统董事会 | 2025-05-09 | — | — | CN | disclosed |
| US-20250138016-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114341625-B | Quantitative raman spectroscopy | 阿尔托大学注册基金会 | 2025-03-11 | — | — | CN | disclosed |
| CN-118671346-B | Metabolic marker for gastric cancer diagnosis and application thereof | 浙江省肿瘤医院 | 2024-11-15 | — | — | CN | disclosed |
| CN-118671346-A | Metabolic marker for gastric cancer diagnosis and application thereof | 浙江省肿瘤医院 | 2024-09-20 | — | — | CN | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024086312-A1 | ENHANCED NAD+ COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIONADRX HOLDINGS, INC. DBA BRYLEOS (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240044902-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230417734-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230417734-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230400438-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. | 2023-12-14 | — | — | US | disclosed |
| EP-4237090-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | Board of Regents, The University of Texas System (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116490776-A | Methods for detecting and treating ovarian cancer | 德州大学系统董事会 | 2023-07-25 | — | — | CN | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230158088-A1 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, ENHANCING DRUG POTENCY AND TREATING VIRAL INFECTIONS, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20220364997-A1 | QUANTITATIVE RAMAN SPECTROSCOPY | AALTO UNIVERSITY FOUNDATION SR (FI) | 2022-11-17 | — | — | US | disclosed |
| WO-2022125057-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125057-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125056-A1 | METHODS AND CONSUMER PRODUCTS FOR DETECTING A METABOLITE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220160617-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2022093960-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093960-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3990899-A1 | QUANTITATIVE RAMAN SPECTROSCOPY | Aalto University Foundation sr (FI) | 2022-05-04 | — | — | EP | disclosed |
| CN-114341625-A | Quantitative Raman spectroscopy | 阿尔托大学注册基金会 | 2022-04-12 | — | — | CN | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| EP-3967217-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3954991-A2 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | Laboratory Corporation of America Holdings (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113156096-A | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-107427221-B | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2021-03-09 | — | — | CN | disclosed |
| WO-2020260625-A1 | QUANTITATIVE RAMAN SPECTROSCOPY | AALTO UNIVERSITY FOUNDATION SR (FI) | 2020-12-30 | — | — | WO | disclosed |
| EP-2881394-B1 | CONDENSED RING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| CN-107427221-A | Blood-based biomarkers for diagnosing coronary atherosclerotic disease | 全球基因集团有限责任公司 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9493439-B1 | Proteasome inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493439-B1 | Proteasome inhibitors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
| EP-2881394-A1 | CONDENSED RING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8497380-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2013-07-30 | — | — | US | disclosed |
| US-8389442-B2 | N-phenyl-′(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION LLC (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389442-B2 | N-phenyl-′(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION LLC (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2013-01-10 | — | — | US | disclosed |
| US-8324394-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-12-04 | — | — | US | disclosed |
| US-20120165539-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2012-06-28 | — | — | US | disclosed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919517-B2 | Indazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919517-B2 | Indazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| EP-1613156-B1 | N-PHENYL- \" (4-PYRIDYL)- AZINYL]AMINE DERIVATIVES AS PLANT PROTECTION AGENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-05-06 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090042883-A1 | ANTITUMOR AGENT | KYOWA HAKKOKOGYO CO. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042883-A1 | ANTITUMOR AGENT | KYOWA HAKKOKOGYO CO. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-7470717-B2 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-7470717-B2 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| WO-2008052072-A9 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARM INC (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008052072-A2 | COMPOUNDS FOR THE TREATMENT OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1852112-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070117856-A1 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117856-A1 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | SYNGENTA CROP PROTECTION, INC. | 2007-02-08 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165539-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | RAB9A 4372/4885NPC1 2936/4885KMT2A 3731/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | RAB9A 2410/4885NPC1 1131/4885KMT2A 1865/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | RAB9A 1530/4885NPC1 1268/4885KMT2A 2259/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | RAB9A 1530/4885NPC1 1268/4885KMT2A 2259/4885 |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | RAB9A 4359/4885NPC1 2847/4885KMT2A 3607/4885 |
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | RAB9A 1598/4885NPC1 1079/4885KMT2A 3681/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | RAB9A 3278/4885NPC1 2385/4885KMT2A 2063/4885 |
| US-12571737-B2 | Quantitative Raman spectroscopy | CWC22, ILF2, IL36G | RAB9A 4182/4885NPC1 3387/4885KMT2A 4487/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | RAB9A 1598/4885NPC1 1079/4885KMT2A 3681/4885 |
| US-20070032490-A1 | N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents | CYP1A1, NAT1, AKR7A2 | RAB9A 579/4885NPC1 347/4885KMT2A 761/4885 |
| US-20070117856-A1 | Indazole derivatives | IGF1R, NR0B2, ADRA2B | RAB9A 2996/4885NPC1 2845/4885KMT2A 1477/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | RAB9A 2410/4885NPC1 1131/4885KMT2A 1865/4885 |
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | RAB9A 585/4885NPC1 1090/4885KMT2A 3994/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | RAB9A 2090/4885NPC1 4880/4885KMT2A 1449/4885 |
| US-20090042883-A1 | ANTITUMOR AGENT | MCL1, HDAC7, TP53 | RAB9A 2761/4885NPC1 1842/4885KMT2A 1021/4885 |
| US-12566161-B2 | Methods and consumer products for detecting a metabolite | SLC6A6, SLC7A11, CTH | RAB9A 1471/4885NPC1 1733/4885KMT2A 3082/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | RAB9A 2264/4885NPC1 1366/4885KMT2A 1071/4885 |
| US-20090082348-A1 | INDAZOLE DERIVATIVES | IGF1R, NR0B2, ADRA2B | RAB9A 2996/4885NPC1 2845/4885KMT2A 1477/4885 |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE3B, PDE5A | RAB9A 4486/4885NPC1 2749/4885KMT2A 3570/4885 |
| US-20150284384-A1 | RING-FUSED HETEROCYCLIC COMPOUND | TRPV1, TRPV2, TRPV3 | RAB9A 785/4885NPC1 1138/4885KMT2A 2063/4885 |
| US-12578322-B2 | Methods and consumer products for detecting a metabolite | SHBG, OXGR1, OGG1 | RAB9A 4417/4885NPC1 4657/4885KMT2A 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.